Palvella COO awarded 48,956 stock options

Palvella Therapeutics Chief Operating Officer Kathleen Goin reported receiving a stock option grant.

Rhea-AI Filing Summary

Palvella Therapeutics Chief Operating Officer Kathleen Goin reported receiving a stock option grant. On February 5, 2026, she was awarded options to purchase 48,956 shares of common stock at an exercise price of $76.43 per share, expiring February 5, 2036.

The options vest in equal monthly installments over 48 months starting February 5, 2026, and each vesting date requires her continued service. All 48,956 derivative securities are held directly following this grant.

Insider Trade Summary

Grant/Award: 48,956 shares

Grant/Award 1 txn

Insider Goin Kathleen

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	48,956	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 48,956 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Palvella Therapeutics (PVLA) disclose in this Form 4?

Palvella Therapeutics disclosed that Chief Operating Officer Kathleen Goin received a stock option grant for 48,956 shares at a $76.43 exercise price. The options were granted on February 5, 2026 and are held directly by her.

How many Palvella (PVLA) stock options were granted to the COO?

Chief Operating Officer Kathleen Goin was granted stock options covering 48,956 shares of Palvella common stock. These options were reported as acquired on February 5, 2026 and all 48,956 derivative securities are shown as beneficially owned following the transaction.

What is the exercise price of Kathleen Goin’s Palvella (PVLA) stock options?

The stock options granted to Kathleen Goin have an exercise price of $76.43 per share. This means she can purchase Palvella common stock at $76.43 for each of the 48,956 optioned shares, subject to vesting and expiration terms.

When do the new Palvella (PVLA) COO stock options vest?

The options vest in equal monthly installments over 48 months starting February 5, 2026. Each monthly vesting is conditioned on Kathleen Goin’s continuous service with Palvella through the applicable vesting date, gradually increasing the exercisable portion over four years.

When do Kathleen Goin’s Palvella (PVLA) stock options expire?

The COO’s stock options expire on February 5, 2036. She may exercise vested portions any time after they vest and before this expiration date, subject to the option terms and her continued service conditions described in the grant’s vesting schedule.

Is the Palvella (PVLA) COO’s stock option ownership direct or indirect?

The filing reports that all 48,956 derivative securities are held with direct ownership. There is no stated indirect ownership entity or footnote disclaimer shifting voting or investment authority; the options are attributed directly to Kathleen Goin.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 04:05 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goin Kathleen

(Last) (First) (Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$76.43	02/05/2026		A		48,956		(1)	02/05/2036	Common Stock	48,956	$0	48,956	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

	/s/ Kathleen A. McGowan, Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.